A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
Clinical trial NCT01080222 · TERMINATED
Trial details
- NCT number
- NCT01080222
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-08-01
- Primary completion
- 2013-10-01
- Enrollment
- 152
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.